Both biosimilar and generic drugs have an abbreviated approval process; however, the clinical trial requirements differ enormously.
Cecil Nick
Advertisement
Cecil Nick is Vice President, Biotechnology, at PAREXEL Consulting.
Articles by Cecil Nick
Advertisement
Latest Updated Articles
- Clinical And Cost Considerations Of Developing A Biosimilar
Published: September 1st 2010 | Updated:
Advertisement
Advertisement
